Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Oregovomab

Monoclonal antibody · Immune activation, directed at CA125 (MUC16) · developed by CanariaBio

Phase 3 Most advanced trial

1 Registered trials

What is Oregovomab?

Oregovomab is a murine monoclonal antibody that binds CA125, a tumor-associated antigen. It is used as a vaccine to stimulate a host cytotoxic immune response against CA125-expressing tumor cells. It is studied in ovarian, fallopian tube, and peritoneal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MAb-B43.13
Drug type: Monoclonal antibody
Targets: CA125 (MUC16)
Mechanism: Immune activation, directed at CA125 (MUC16)
Pathways: immune_activation
Therapy area: Oncology
Developer: CanariaBio Inc.
In trials of: IQV
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: HX101E7L6S

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04498117	Phase 3	Carcinoma, Ovarian Epithelial	Active not recruiting	IQV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, Ovarian EpithelialFallopian Tube AdenocarcinomaFallopian Tube NeoplasmsFallopian Tube Serous AdenocarcinomaOvarian CancerOvarian NeoplasmsOvarian Serous AdenocarcinomaPeritoneal CancerPeritoneal CarcinomaPeritoneal Neoplasms

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z